A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Summary

The study is being conducted to evaluate whether the efficacy of SHR-A1811 is better than Pyrotinib in combination with Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane.

Timeline

Start

2022-08-04

Primary completion

2026-12-31

Completion

2027-12-31

Publications

• Yao H, Zhang Q, Li H, Yin Y, Wang S, Ouyang Q, Sun T, Li W, Wang X, Yan M, Wang B, Cheng J, Tong Z, Wei W, Wang X, Xie W, Sun Z, Yuan P, Geng C, Gan L, Han X, Li W, Zhou S, Yan X, Gao J, Yi T, Wu J, Niu Z, Fu F, Nie J, Wang Y, Zhao B, Wu Z, Zhu Z, Yang Y, Zhao J, Sheng Z, Zhang Y, Cheng L, Zhu X, Song E. Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2026 Jul 1:S1470-2045(26)00193-2. doi: 10.1016/S1470-2045(26)00193-2. Online ahead of print.

Drugs

Indications